Orbem raises €55.5M Series B to scale AI-powered MRI technology

Munich-based Orbem, a deeptech company applying artificial intelligence to magnetic resonance imaging to analyse food and biological systems, has closed a €55.5 million Series B financing round. The round was led by Innovation Industries, with participation from Supernova Invest and follow-on investments from existing backers, including General Catalyst, 83North, The Venture Collective, Possible Ventures, and a group of angel investors.

Orbem applies artificial intelligence to industrialise magnetic resonance imaging, enabling fast, scalable, and non-invasive analysis of biological materials. Its platform generates actionable insights from biological data to support decision-making across agriculture, food production, and health.

The technology provides access to information that was previously unavailable at an industrial scale, such as determining embryo sex in eggs, evaluating seed viability, or assessing produce quality without destructive testing. With proven applications in the poultry industry, Orbem’s solutions help improve efficiency, reduce waste, and increase transparency across biological value chains.

Its flagship product, Genus Focus, uses AI-enabled MRI to determine the sex of a poultry egg non-invasively in under one second, providing an alternative to the culling of male chicks, a practice restricted in parts of the European Union. To date, the system has been used to scan more than 170 million eggs, and the company is expanding capacity to meet growing international demand.

Building on this foundation, Orbem has introduced Genus Scale, a solution designed to assess egg fertilisation status before incubation. This allows hatcheries to identify non-viable eggs early, reduce inefficiencies, and redirect suitable eggs for food use.

The Series B funding will support Orbem’s expansion into the United States, further scaling of its poultry solutions, and entry into the fruit and vegetable sector using non-destructive quality analysis. The company will also continue developing healthcare applications based on large-scale biological data.